News
Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform
10 Apr 24
News, Upgrades, Analyst Ratings
The Latest Analyst Ratings For Ionis Pharmaceuticals
9 Apr 24
Analyst Ratings
Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $75
9 Apr 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Ionis Pharmaceuticals Announced Olezarsen 80 Mg Monthly Dose Met The Primary Endpoint Of Significantly Reducing Triglycerides In Patients With Genetically Validated Fcs At Six Months
7 Apr 24
News
Ionis Pharmaceuticals To Present Olezarsen Phase 3 Data In Familial Chylomicronemia Syndrome At 2024 American College of Cardiology Annual Meeting
25 Mar 24
Biotech, News, Events, General
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
13 Mar 24
Biotech, Large Cap, News, Health Care, Movers, General
Ionis Announces Results from Phase 2 Study of ION224, an Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH/MASH
13 Mar 24
News
Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $72
6 Mar 24
News, Price Target, Analyst Ratings
Oppenheimer Reinstates Outperform on Ionis Pharmaceuticals, Raises Price Target to $65
26 Feb 24
News, Price Target, Initiation, Analyst Ratings
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
22 Feb 24
Analyst Ratings
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
22 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Earnings Scheduled For February 21, 2024
21 Feb 24
Earnings
Press releases
Ionis Publishes 2023 Corporate Responsibility Report
25 Apr 24
Press Releases
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
7 Apr 24
Press Releases
Ionis to hold olezarsen Phase 3 data webcast
28 Mar 24
Press Releases
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
25 Mar 24
Press Releases
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
13 Mar 24
Press Releases
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
6 Mar 24
Press Releases, General
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
29 Feb 24
Press Releases
Ionis to present at upcoming investor conferences
28 Feb 24
Press Releases
Ionis reports fourth quarter and full year 2023 financial results
21 Feb 24
Earnings, Press Releases
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
15 Feb 24
Press Releases
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
8 Feb 24
Press Releases
Ionis to hold fourth quarter and full year 2023 financial results webcast
7 Feb 24
Press Releases